Evidence map›Paper›PMID 37332025›Full record

ArticleAnnals of surgical oncology2023

Is Pathologic Complete Response a Good Predictor for the Long-Term, Clinical Outcome in Patients with Gastric Cancer After Neoadjuvant Chemotherapy? A Retrospective, Multi-institution Study in China.

Chao Lin, Junjun Ma, Chunchao Zhu, Xuan Zhao, Yueda Chen, Lu Zang, Fenglin Liu

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Chao Lin *Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Junjun Ma *Department of General Surgery, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China.
Chunchao Zhu *Department of General Surgery, Renji Hospital, Shanghai Jiaotong University, Shanghai, China.
Xuan ZhaoDepartment of General Surgery, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China.
Yueda ChenDepartment of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, China.
Lu ZangDepartment of General Surgery, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China. zanglu@yeah.net.
Fenglin LiuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. liu.fenglin@zs-hospital.sh.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany studies have used pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) as the primary endpoint for the short-term efficacy in gastric cancer, but whether it is a good indicator for overall survival is poorly understood.

methodsThis study reviewed a multi-institution database of patients who underwent radical gastrectomy and achieved pCR after NAC. Cox regression models were used to identify clinicopathologic predictors of overall survival (OS) and disease-free survival (DFS). Survival curves were calculated by using the Kaplan-Meier method and compared by means of the log-rank test.

resultsOS and DFS in patients with pCR were significantly higher than in those with non-pCR (both P < 0.001). Multivariable analysis confirmed pCR was an independent prognostic factor for OS and DFS (P = 0.009 and P = 0.002 for OS and DFS, respectively). However, the survival benefit for pCR was present only for ypN0 tumors (P = 0.004 and P = 0.001 for OS and DFS, respectively), and OS (P = 0.292) and DFS (P = 0.285) among patients with ypN+ gastric cancer could not be stratified by pCR.

conclusionsIn our study, pCR is an independent prognostic factor for OS and DFS, but the survival benefit for pCR is present only for ypN0 tumors but not ypN+ tumors.

Indexed as

Neoadjuvant TherapyStomach NeoplasmsDisease-Free SurvivalHumansPrognosisProportional Hazards ModelsRetrospective StudiesGastric cancerNeoadjuvant chemotherapyOverall survivalPathologic complete responsePrognosis

Identifiers

PMID37332025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.